AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in th…
ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Co…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
- Restructuring Provides Parallel Rights to Manufacture and Sell doggybone DNA (dbDNA™) into the AAV market as Independe…
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-a…
. - Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus op…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced…